Abstract
Investigators assessed the efficacy and safety of piperacillin/tazobactam therapy in a study of patients with community-acquired lower respiratory tract infections and a study of patients with nosocomial, severe lower respiratory tract infections. Piperacillin 4 g/tazobactam 500 mg was given intravenously every 8 h to 193 hospitalized lower respiratory tract infection patients for a minimum of 5 days. There was a favorable response rate of 97% and eradication of the causative pathogen was documented or presumed in 93% of patients. There was a low incidence of adverse experiences and the combination was well tolerated. Seventy-one intensive care patients with severe lung disease received 4 g piperacillin/500 mg tazobactam intravenously every 6 h; afterward they were given amikacin 7.5 mg/kg every 12 h. Minimum duration of treatment was 5 days. Therapy with piperacillin/tazobactam plus amikacin was well-tolerated, produced a 74% favorable clinical response rate, and eradicated the responsible pathogen in 70% of patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Neu HC (1991) Therapy and prophylaxis of bacterial infections. In: Wilson JD, Braunwald E, Isselbacher KJ, Petersdorf RG, Martin JB, Fauci AS, Root RK (eds) Harrison's principles of internal medicine, 12th edn. McGraw-Hill, New York, pp 485
Williams JD (1989) Antimicrobial resistance: possible clinical uses of beta-lactamase inhibitors. Presented at the Biennial Conference on Chemotherapy of Infectious Disease and Malignancies. Montreux, Switzerland
Fass RJ, Prior RB (1989) Comparative in vitro activities of piperacillin/tazobactam and ticarcillin/clavulanate. Presented at the Biennial Conference on Chemotherapy of Infectious Disease and Malignancies. Montreux, Switzerland
Jones RN, Pfaller MA, Fuchs PC, Aldridge K, Allen SD, Gerlach EH (1989) Piperacillin/tazobactam (YTR 830) combination: comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 bacteroides fragilis group strains. Diagn Microbiol Infect Dis 12:489–494
Apelbaum PC, Spangler SK, Jacobs MR (1991) Susceptibilities of 394 bacteroides fragilis, non-B. fragilis group bacteroides species, and fusobacterium species to newer antimicrobial agents. Antimicrob Agents Chemother 5:1214–1218
Kuck NA, Jacobus NV, Petersen PJ, Weiss WJ, Testa RT (1989) Comparative in vitro and in vivo activities of piperacillin combined with the β-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob Agents Chemother 33:1964–1969
Reynolds HY (1991) Pneumonia and lung abscess. In: Wilson JD et al (eds) Harrison's principles of internal medicine. McGraw-Hill, New York, pp 1067
Winter JH (1991) The scope of lower respiratory tract infection. Infection 19[Suppl 7]:359–364
Mouton Y, Leroy O, Beuscart C, Chidiac C, Senneville E, Ajana F, Lecocq P (1993) Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections. J Antimicrob Chemother 31[Suppl A]:87–95
Craven DE, Steger KA, Barber TW (1991) Preventing nosocomial pneumonia: state of the art and perspectives for the 1990s. Am J Med 91[Suppl 3B]:44–53
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sanders, C.V. Piperacillin/tazobactam in the treatment of community-acquired and nosocomial respiratory tract infections: A review. Intensive Care Med 20 (Suppl 3), S21–S26 (1994). https://doi.org/10.1007/BF01745247
Issue Date:
DOI: https://doi.org/10.1007/BF01745247